These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Gastroesophageal reflux disease: the roles of motility in pathophysiology and therapy. Quigley EM Am J Gastroenterol; 1993 Oct; 88(10):1649-51. PubMed ID: 8213704 [No Abstract] [Full Text] [Related]
28. [Manometric evaluation of the action of metoclopramide in gastroesophageal reflux patients]. Larraín A; Uribe P; Wunkhaus R; Ayala M Rev Med Chil; 1973 Feb; 101(2):129-31. PubMed ID: 4731771 [No Abstract] [Full Text] [Related]
29. Transient lower oesophageal sphincter relaxation reducers--have we hit a brick wall? Hershcovici T; Fass R Aliment Pharmacol Ther; 2011 Jun; 33(11):1256-7; author reply 1257-8. PubMed ID: 21535056 [No Abstract] [Full Text] [Related]
30. [Pathophysiology, clinical aspects and therapy of gastro-esophageal reflux disease]. Fahrländer H Schweiz Med Wochenschr; 1981 Apr; 111(16):550-5. PubMed ID: 7233133 [TBL] [Abstract][Full Text] [Related]
31. [Functional esophageal exploration in the assessment of gastroesophageal reflux]. Panzer JM Rev Med Brux; 1994; 15(1):10-3. PubMed ID: 8191166 [TBL] [Abstract][Full Text] [Related]
32. The effect of metoclopramide on the lower oesophageal sphincter in late pregnancy. Brock-Utne JG; Dow TG; Welman S; Dimopoulos GE; Moshal MG Anaesth Intensive Care; 1978 Feb; 6(1):26-9. PubMed ID: 665973 [TBL] [Abstract][Full Text] [Related]
33. Effect of clebopride on lower esophageal sphincter pressure. Ribeiro V; da Silva AL; Castro Lde P Arq Gastroenterol; 1981; 18(2):71-4. PubMed ID: 7332503 [TBL] [Abstract][Full Text] [Related]
34. [Gastroesophageal reflux. Evaluation of treatment with pirenzepine by continuous ambulatory monitoring of the pH]. García Albarrán ; Ruiz de León ; Díaz Rubio Rev Esp Enferm Apar Dig; 1987 Oct; 72(4 Pt 1):303-7. PubMed ID: 3685599 [No Abstract] [Full Text] [Related]
35. SR 48692, a specific neurotensin receptor antagonist, has no effect on oesophageal motility in humans. Zerbib F; Piche T; Charles F; Galmiche JP; Bruley des Varannes S Aliment Pharmacol Ther; 2004 Apr; 19(8):931-9. PubMed ID: 15080855 [TBL] [Abstract][Full Text] [Related]
36. Metoclopramide in gastroesophageal reflux of infancy. Machida HM; Forbes DA; Gall DG; Scott RB J Pediatr; 1988 Mar; 112(3):483-7. PubMed ID: 3346792 [TBL] [Abstract][Full Text] [Related]
37. [Effect of antidopaminergic drugs and H2 blockers on esophageal motility and gastroesophageal sphincter]. Braghetto I; Henríquez A; Espinoza M; Csendes A Rev Med Chil; 1985 May; 113(5):428-32. PubMed ID: 2869561 [No Abstract] [Full Text] [Related]
38. [Reproducibility of oesophageal sphincter pressure and gastrooesophageal reflux (author's transl)]. Pflücke F Dtsch Z Verdau Stoffwechselkr; 1982; 42(1):1-6. PubMed ID: 7075522 [No Abstract] [Full Text] [Related]
39. Metoclopramide: a dopamine receptor antagonist. DiPalma JR Am Fam Physician; 1990 Mar; 41(3):919-24. PubMed ID: 2407079 [TBL] [Abstract][Full Text] [Related]
40. Metoclopramide in gastroesophageal reflux disease: rationale for its use and results of a double-blind trial. McCallum RW; Fink SM; Winnan GR; Avella J; Callachan C Am J Gastroenterol; 1984 Mar; 79(3):165-72. PubMed ID: 6367434 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]